UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-KSB

     (Mark One)

     [ X ] Annual report under Section 13 or 15(d) of the Securities Exchange
Act of 1934

     For the fiscal year ended December 31, 2001

     [    ] Transition report under Section 13 or 15(d) of the Securities
Exchange Act of 1934

     For the transition period from _________ to _________

     Commission File No. 0-30728


                                  PROTEO, INC.
                 (Name of Small Business Issuer in Its Charter)

          NEVADA                                      88-0292249
(State or Other Jurisdiction of                     (IRS Employer
Incorporation or Organization)                 Identification Number)

                         2775 MESA VERDE EAST, F#101
                        COSTA MESA, CALIFORNIA, 92626
              (Address of Principal Executive Offices) (Zip Code)

                              (949) 979-7074
                       (Issuer's Telephone Number)
           SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
                                   (None)

           SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
                        Common Stock, par value $0.001
                            (Title of Class)

     Check  whether  the  issuer  (1)  filed all reports required to be filed by
Section  13  or 15(d) of the Exchange Act during the past 12 months (or for such
shorter  period  that the registrant was required to file such reports); and (2)
has  been  subject  to  such  filing  requirements  for  the  past  90  days.

     Yes  [ X ]   No  [  ]

     Check  if  there is no disclosure of delinquent filers pursuant to Item 405
of  Regulation  S-B  is  not  contained  in this form, and no disclosure will be
contained,  to  the  best  of  registrant's  knowledge,  in  definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or  any  amendment  to  this  Form  10-KSB.  [  X  ]

     State  issuer's  revenues  for  its  most  recent  fiscal  year.     $  -0-

     State  the  aggregate  market  value of voting and non-voting common equity
held  by  non-affiliates  computed by reference to the price at which the common
equity  was  sold, or the average bid and asked prices of such common equity, as
of  a  specified  date within the past 60 days.  (See definition of affiliate in
rule 12b-2 of the Exchange Act.)  As of March 31, 2002, the Issuer had 7,325,444
shares of common stock held by non-affiliates.  There does not currently exist a
stable  market  for  which  to accurately determine the Issuer's market value at
this  time.

     State  the  number of shares outstanding of each of the issuer's classes of
common  equity,  as  of  the  latest  practicable  date.  20,414,444

                       DOCUMENTS INCORPORATED BY REFERENCE

     If  the following documents are incorporated by reference, briefly describe
them  and  identify  the  part of the form 10-KSB (e.g., Part I, Part II, etc. )
into  which  the  document  is  incorporated:  (1) any annual report to security
holders;  (2)  any  proxy or information statement; and (3) any prospectus filed
pursuant to rule 424(b) or (c) of the Securities Act of 1933 ("Securities Act").
The  listed  documents  should  be clearly described for identification purposes
(e.g.,  annual  report  to  security  holders for fiscal year ended December 24,
1990).

None.

     Transitional  Small  Business  Disclosure  Format  (check  one):

Yes No  [ X ]

<PAGE>

                                TABLE OF CONTENTS

                                     PART I


Item 1          Description of Business.

Item 2          Description of Property

Item 3          Legal Proceedings

Item 4          Submission of Matters to a Vote of Security Holders.

                                     PART II

Item 5          Market for Common Equity and Related Stockholder Matters.

Item 6          Management's Discussion and Analysis or Plan or Operations.

Item 7          Financial Statements.

Item 8          Changes In and Disagreements With Accountants on Accounting and
Financial Disclosure.


                                    PART III

Item 9          Directors, Executive Officers, Promoters and Control Persons;
Compliance with Section
          16(a) of the Exchange Act.

Item 10        Executive Compensation

Item 11        Security Ownership of Certain Beneficial Owners and Management.

Item 12        Certain Relationships and Related Transactions.

Item 13        Exhibits and Reports on Form 8-K.

<PAGE>


                                     PART  I

This Annual Report includes forward-looking statements within the meaning of the
Securities Exchange Act of 1934 (the "Exchange Act"). These statements are based
on  management's beliefs and assumptions, and on information currently available
to  management.  Forward-looking  statements  include the information concerning
possible  or assumed future results of operations of the Company set forth under
the  heading  "Financial  Information-Management's  Discussion  and  Analysis of
Financial  Condition and Results of Operations." Forward-looking statements also
include  statements  in  which words such as "expect,"  "anticipate,"  "intend,"
"plan,"  "believe,"  "estimate,"  "consider"  or  similar  expressions are used.

Forward-looking  statements  are  not  guarantees  of  future  performance. They
involve  risks, uncertainties and assumptions.  The Company's future results and
shareholder  values  may  differ  materially  from  those  expressed  in  these
forward-looking  statements.  Readers are cautioned not to put undue reliance on
any  forward-looking  statements.

ITEM 1 - DESCRIPTION OF BUSINESS

COMPANY  OVERVIEW

     Proteo, Inc. (the "Company") is a Nevada corporation formed on December 18,
1992.  The  Company was originally incorporated as The Flintlock Company.  Later
it  was  necessary  for  the  Company  to  change  its  name to The Old American
Flintlock  Company when it was reinstated on January 9, 1996.  Then, on February
12,  1998,  the  Company changed its name to American Flintlock Company.  On May
18,  1999,  the  Company  changed  its name to Page Active Holdings, Inc.  On or
about  July 11, 2002, the Company changed its name to Trivantage Group, Inc.  On
January  15,  2002,  in  anticipation  of  a share exchange with Proteo, Inc., a
Nevada  corporation  ("Old Proteo") which was effectuated on April 25, 2002 (the
"Share Exchange"), the Company changed its name to Proteo, Inc.  Previously, the
Company has been in the developmental stage since inception and has little or no
operating  history  other  than organizational matters.  Subsequent to the Share
Exchange,  the  Company  will  continue research and development of Old Proteo's
pharmaceuticals  based  on  the  human  protein  Elafin.

     Old  Proteo was incorporated in the State of Nevada and began operations in
November  2000.  In  December 2000, Old Proteo entered into a Reorganization and
Stock Exchange Agreement with Proteo Biotech AG, a German corporation located in
Kiel,  Germany.  Pursuant to the terms of the agreement, all of the shareholders
of  Proteo Biotech AG exchanged their common stock for an aggregate of 2,500,000
shares  of  Old  Proteo's  common  stock.  As  a  result, Proteo Biotech AG (the
"Subsidiary") is currently a wholly owned subsidiary of Old Proteo, which is now
a  wholly  owned  subsidiary  of  the  Company.

DESCRIPTION  OF  BUSINESS

     The Company and the Subsidiary intend to develop, manufacture, promote, and
market  pharmaceuticals  and other biotech products.  However, we do not believe
that  any  of  our planned products will produce sufficient revenues in the next
six  years  to  support  us financially.  We currently expect to only sell small
quantities  of  these  products  in  the first few business years.  We intend to
identify  and  develop  other  potential  products.  To  achieve  profitable
operations,  the  Company,  independently  or in collaboration with others, must
successfully  identify,  develop,  manufacture, and market proprietary products.
The  products  and  technologies  we  intend to develop will require significant
commitments  of  personnel  and  financial  resources.

     Our  business  strategy  is  focused  on the development of pharmaceuticals
based on human protein.  Specifically, we intend to initially focus our research
on  the development of drugs based on the human protein Elafin.  We believe that
Elafin  may  be  useful in the treatment of cardiac infarction, serious injuries
caused  by accidents, post-surgery damage to tissue, and complications resulting
from  organ  transplantation.

     Elafin  is  a  human protein that naturally occurs in human skin, lungs and
the  mammary gland.  Elafin is an elastase inhibitor which inhibits the activity
of  two  enzymes  called  elastase  and proteinase 3.  Both of these enzymes are
known  to  be  involved  in  the  breakdown  of  tissue  in various inflammatory
diseases.  Elafin is believed to protect cells containing it against destruction
by  these  enzymes.  We  intend  to utilize Elafin as a drug in the treatment of
various  diseases  and  injuries.

     We  believe that Elafin may be useful as a drug in the treatment of cardiac
infarction.  Cardiac infarction appears as a result of deficiencies in the blood
supply of heart muscles caused by damage to the supplying coronary vessels.   As
an  immediate  result,  the  heart  weakens and the heart muscles are destroyed.
Damage  to  tissue caused by cardiac infarction will slowly form scars.  Current
methods  of  treatment  are  aimed  at  restoring the blood supply to the heart,
either  by  replacement with new blood vessels (bypass surgery) or by removal of
blood-clots in the coronary vessels (lyse therapy).  Utilizing this methods, the
mortality  of  patients  suffering  from  cardiac  infarction  is  reduced  from
approximately  8%  to  12%  during clinical treatment.  The remaining deaths are
mainly  a  result  of  inflammation  of  the  heart  muscle  after  the  cardiac
infarction,  which causes the destruction of the affected muscle tissue.  Animal
experiments  have  shown  that  Elafin  may be effective in protecting the heart
muscles  against  destruction  after  blood  supply  was  interrupted.

     Elafin  may  also  be  useful  in  the  treatment of the seriously injured.
Similar to damage of heart muscles as described above, much of the damage caused
by  serious  injuries  appear  after  the  injury  causing  event (e.g.: traffic
accidents).  In emergency treatment following accidents, the blood supply, nerve
fibers  and  the stability of bones and joints are given priority.  Due to blood
supply  deficiencies,  inflammation will occur in injured muscles and in injured
vessels.  Because  muscles  may be destroyed by the inflammation, limbs may have
to  be  amputated  despite  successful  surgeries.  Elafin  may  protect muscles
against  damage caused by inflammation.  In animal experiments, rat legs treated
with Elafin remained almost unaffected, although the blood supply of the leg was
cut  off  for  six  hours.

     Elafin  may  also  be  used  in  the  course  of heart transplantation.  To
transplant  hearts  successfully,  simultaneous treatment with anti-inflammatory
drugs  is  necessary.  Inflammations  of  transplanted  organs are mainly caused
either  by  rejection  of  the  organ  by  the  immune system or by blood supply
deficiencies  during the transplantation.  Although various drugs are used today
to  avoid  the  rejection of the organ, such rejections still occur quite often.
Therefore,  additional anti-inflammatory drugs are needed, which may potentially
prevent  damages  caused  by blood supply deficiencies.  Animal experiments have
shown  that  treatment  solely  with  Elafin may avoid rejection of transplanted
hearts.

     Other  preliminary data indicate that Elafin may be useful in a broad range
of other applications whether pharmaceutical or not.  Therefore, we will attempt
to encourage other scientists, research centers as well as other companies to do
research  and development on Elafin for other applications than described above.
For  example,  Elafin  may  also be effective in the treatment of dermatological
diseases  and  defects,  or  as  ingredient  in  cosmetics.

     Proteo  owns  licenses to exclusively develop products based on patents and
filings  relating  to  Elafin, including nine patents already issued and another
four  patent  applications  already in the process of patent office reviews.  Of
the  issued  patents,  two  patents  were  issued  in  the  U.S.

     Further,  Proteo intends to engage in the research and development of other
drugs  and biotechnical products based on human protein.  We may also be able to
implement  unique  technologies  and biotechnological production procedures that
may  enable  the  Company  to  offer  related  services  to  other  companies.

     We  have  received  a  grant  in  the amount of 766,000 Euro (approximately
$700,000)  from  the  government  of the German state Schleswig-Holstein for the
research  and  pre-clinical  development of the our pharmaceuticals based on the
human protein Elafin.  Such grant required that the Company prove its economical
ability  to  cover  at  least 50% of the project costs on its own as well as the
achievement  of  milestones.  The  grant will be paid as reimbursement of 50% of
related  expenses  over  the  next  two  years.

     Initially,  Proteo  will focus on the development of a production procedure
for  Elafin  and  the  initiation  of  clinical  trials  to achieve governmental
approval  for  the  use  of  Elafin  as a drug.  After development of production
procedures  have  been achieved, we will initiate pre-clinical and subsequently,
Phase  1,  2, and 3 clinical trials to determine the safety and effectiveness of
Elafin  as  a  drug.

     Our goals for German (CE Mark) approval on our initial product designed for
patients  suffering  from  serious  injuries is targeted for 2007 and U.S. (FDA)
approval  in  2010.  It  should  be  noted that this specialized application, if
successfully developed, would have a market potential substantially smaller than
the  overall  market  of Elafin for more widespread applications such as for the
treatment  of  cardiac  infarction.

THE  SUBSIDIARY

     In  December  2000, Old Proteo entered into a stock exchange agreement with
the  shareholders  of  Proteo  Biotech  AG  and  acquired  all of the issued and
outstanding  capital  stock of Proteo Biotech AG, a German corporation, with its
principal place of business located in Kiel, Germany.  Proteo Biotech AG will be
the  only  subsidiary  of  Proteo.

     Proteo  Biotech  AG  was formed in Kiel, Germany, on April 6, 2000.  Proteo
Biotech  AG is in the business of developing a pharmaceutical based on the human
protein  called  Elafin  and  possible  by-products  thereof  as well as related
technologies.  The  President  and  CEO of Proteo Biotech AG is currently Ulrich
Glaeser.  The directors of Proteo Biotech AG are Prof. Oliver Wiedow, MD., Birge
Bargmann  and  Barbara  Kahlke,  MD.

     To  date,  our  Subsidiary  has  not  had  any  profitable  operations.
Furthermore, we do not anticipate that we will have profitable operations in the
near  future.

COLLABORATION  WITH  OTHER  COMPANIES

     In  an  effort  to  provide  the  Company  with  some revenue which will be
utilized  in  the  implementation  of  our  business  plan, our Subsidiary plans
periodically to provide research and development and manufacturing services as a
sub-contractor  and/or consultant to unaffiliated companies which do not compete
with  the Company.  We plan to explore such opportunities if deemed advantageous
to  the  Company.

COMPETITION

     The market for our planned products and technologies is highly competitive,
and  we  expect competition to increase.  We will compete with many other health
care research product suppliers, most of which will be larger than Proteo.  Some
of  our  anticipated  competitors  offer  a  broad range of equipment, supplies,
products  and  technology,  including  many  of  the  products  and technologies
contemplated  to be offered by us.  To the extent that customers exhibit loyalty
to  the  supplier  that  first  supplies  them  with  a  particular  product  or
technology,  our  competitors  may have an advantage over Proteo with respect to
such products and technologies.  Additionally, many of our competitors have, and
will  continue  to  have, greater research and development, marketing, financial
and  other  resources  than  us  and,  therefore, represent and will continue to
represent  significant  competition  in our anticipated markets.  As a result of
their size and the breadth of their product offering, certain of these companies
have  been  and  will  be able to establish managed accounts by which, through a
combination  of  direct computer links and volume discounts, they seek to gain a
disproportionate  share of orders for health care products and technologies from
prospective  customers.  Such  managed  accounts present significant competitive
barriers  for  us.  It  is  anticipated  that  we  will  benefit  from  their
participation  in  selected  markets,  which,  as  they  expand, may attract the
attention  of  our  competitors.  The  business  of  research and development of
pharmaceuticals  for  the  treatment  of  cardiac  infarction  is  intensely
competitive.  Major  companies with immense financial and personal resources are
also  engaged  in  this  field.

     Currently,  we  are not aware of any substance available in the market with
similar  effectiveness to Elafin.  Elastase inhibitors such as Elafin, which may
be  applied  to  humans,  have  been  under  research  and  development  in  the
pharmaceutical  industry  for  more  than ten years.  Currently, there have been
more  than  200  related patents granted.  Most of these substances are produced
synthetically,  and  are not applicable in the treatment of cardiac infarctions.
Three  other  elastase  inhibitors,  secretory  leukoprotease  inhibitor (SLPI),
alpha-1-antitrypsin  and  recombinant  monocyte/neutrophil  elastase  inhibitor
(rM/NEI),  are  similar  to  Elafin in that they are of human descent and may be
applied  like  Elafin  principally.  Three  other  substances under development,
ZD8321,  ZD0892  and ONO-5046 are artificial elastase inhibitors, which may have
comparable  effectiveness  to  that  of  Elafin.

Secretory  Leukoprotease  Inhibitor  (SLPI)

     Amgen,  Inc.  is  the  owner  of the patent for SLPI.  Amgen purchased this
patent  by  acquiring  Synergen,  Inc.  SLPI  is  quite  similar  to  Elafin.
Nevertheless,  SLPI  has  some  disadvantages in its intended application in the
treatment  of  cardiac infarctions and in the treatment of serious injuries.  It
is  only  effective  against  one  (leukocyte-elastase)  of  the  two
(leukocyte-elastase  and proteinase 3) major enzymes which destroy tissue, while
Elafin  has  shown  effectiveness against both. Therefore, Elafin is probably of
higher  effectiveness.  Furthermore, SLPI is not as stable as Elafin, which is a
disadvantage  in  its  distribution as a drug.  SLPI was discovered much earlier
than  Elafin,  therefore,  the  remaining  term of the covering patent should be
shorter  than that related to Elafin.  Amgen does not mention the development of
SLPI  as  a  drug  in  its  annual  report  of  1998.

Alpha-1-antitrypsin

     Human  blood  contains  relatively  large  amounts  of  alpha-1-antitrypsin
naturally.  Research  into  the use of alpha-1-antitrypsin  for the treatment of
cardiac  infarctions,  shock and of other serious inflammations has been ongoing
for  the  last  twenty  years.  Compared  to  Elafin,  however,  there  are some
substantial  problems  related  to  alpha-1-antitrypsin.  For  example,
alpha-1-antitrypsin  is  not  as  stable  as  Elafin,  and  therefore,  from the
scientific  point  of  view  it  is  probably  not  as  effective  as  Elafin.
Additionally,  alpha-1-antitrypsin  is  very  difficult to produce. The existing
biotechnological  procedure to produce alpha-1-antitrypsin is to use genetically
manipulated  sheep, which produce  1-Antitrypsin in their milk.  Existing flocks
of sheep do not produce sufficient amounts of alpha-1-antitrypsin.  As a result,
experiments  involving cloning of sheep (such as "Dolly") have been performed to
produce  a  better  flock  of  sheep  compatible  with  the  production  of
alpha-1-antitrypsin.

Recombinant  monocyte/neutrophil  elastase  inhibitor  (rM/NEI)

     This  compound  of human descent is currently under development for the use
in cystic fibrosis and to be applied by inhalation devices. IVAX Corporation has
entered into a license option agreement with the Center for Blood Research, Inc.
(CBR),  an  affiliate  of the Harvard Medical School, which holds the rights for
this  compound.

ZD8321  and  ZD0892

     Both  ZD8321  and  ZD0892  have  been  developed  by  AstraZeneca  with the
intention  of  treating  lung  diseases.  However,  AstraZeneca  has  recently
suspended  both  inhibitors  from  their  research  and  development  pipeline.

ONO-5046  (Sivelestat)

     Ono  Pharmaceutical  Co.  Ltd., Japan is currently developing the synthetic
elastase  inhibitor  ONO-5046  (Sivelestat)  for  the  use  in adult respiratory
distress  syndrome  and acute lung injury. In 2000 Eli Lilly has signed a letter
of  intent  with ONO Pharmaceutical Co., Ltd., on the development, manufacturing
and  marketing  of  Sivelestat.

GOVERNMENT  REGULATION

     Proteo  and  the  Subsidiary  are,  and  will  continue  to  be, subject to
governmental  regulation  under  the  Occupational  Safety  and  Health Act, the
Environmental  Protection  Act,  the  Toxic  Substances  Control  Act, and other
similar  laws  of general application, as to all of which Proteo believes it and
the  Subsidiary  are  in  material  compliance.  Any  future of, and the cost of
compliance with, these laws and regulations could have a material adverse effect
on the business, financial condition, and results of operation of Proteo and the
Subsidiary.

     Because  of  the  nature of the operations of Proteo and the Subsidiary and
the  use  of hazardous substances and their ongoing research and development and
manufacturing  activities,  Proteo  and  the Subsidiary are subject to stringent
federal,  state  and  local  laws, rules, regulations and policies governing the
use,  generation,  manufacturing,  storage,  air  emission,  effluent discharge,
handling  and  disposal of certain materials and wastes. Although it is believed
that  Proteo  and  the Subsidiary are in material compliance with all applicable
governmental  and environmental laws, rules, regulations and policies, there can
be  no  assurance  that  the  business,  financial  conditions,  and  results of
operations  of  Proteo  and  the  Subsidiary  will  not  be materially adversely
affected  by  current  or  future  environmental  laws,  rules,  regulations and
policies,  or  by  liability occurring because of any past or future releases or
discharges  of  materials  that  could  be  hazardous.

     Additionally,  the  clinical  testing, manufacture, promotion and sale of a
significant  majority  of  the  products  and  technologies  of  Proteo  and the
Subsidiary, if those products and technologies are to be offered and sold in the
United  States,  are  subject  to  extensive regulation by numerous governmental
authorities  in  the United States, principally the FDA, and corresponding state
regulatory agencies. Additionally, to the extent those products and technologies
are to be offered and sold in markets other than the United States, the clinical
testing, manufacture, promotion and sale of those products and technologies will
be  subject  to similar regulation by corresponding foreign regulatory agencies.
In general, the regulatory framework for biological health care products is more
rigorous  than  for  non-biological  health care products. Generally, biological
health care products must be shown to be safe, pure, potent and effective. There
are numerous state and federal statutes and regulations that govern or influence
the  testing,  manufacture,  safety,  effectiveness,  labeling,  storage, record
keeping,  approval, advertising, distribution and promotion of biological health
care  products. Non-compliance with applicable requirements can result in, among
other  things,  fines,  injunctions,  seizures  of  products,  total  or partial
suspension  of  product marketing, failure of the government to grant pre-market
approval,  withdrawal  of  marketing  approvals,  product  recall  and  criminal
prosecution.

PATENTS,  LICENSES  &  ROYALTIES

     The  Subsidiary  owns  licenses  to  exclusively  develop products based on
patents  and  filings including nine (9) patents already issued and another four
(4) patent applications already in the process of patent office reviews.  Of the
issued  patents  are  two  (2)  patents  which  have  been  issued  in  the U.S.

     Prof. Wiedow, a director of the Company, will receive three percent (3%) of
the  gross  revenues of Proteo and the Subsidiary from products based on patents
of  which  he  was  the  principal  inventor. Further, Prof. Wiedow will receive
license fees in the amount of approx. $100,000 (  110,000) per year and a refund
for  all  expenses  to  maintain  the  patents (patent fees, lawyers fees, etc.)

     AstraZeneca  Inc. (formerly Zeneca Inc., formerly ICI Pharmaceuticals Inc.)
had  held  the  patents  for  elafin  for  several  years  and has significantly
contributed  to  the current knowledge. Therefore, AstraZeneca Inc. will receive
two  percent  (2%)  of  the  gross  revenues  of  Proteo and the Subsidiary from
products  based  on  patents  in  which Prof. Wiedow was the principal inventor.

Proteo holds an exclusive license of those patents:

USA          US     5464822
USA          US     6245739
EU           EP     0402068
Japan        JP     2989853
Australia    AU     636148
Canada       CA     2018592
Finland      FI     902880
Ireland      IE     070520
Israel       IL     094602
New Zealand  NZ     233974
Norway       NO     177716
Portugal     PT     094326
South Africa ZA     9004461

EMPLOYEES

     Currently,  Proteo  has  one  full time employee, and Proteo Biotech AG has
five  employees. We expect the number of employees in the Subsidiary to increase
to  six  in  2002.

ITEM  2  -  DESCRIPTION  OF  PROPERTY

The  Company  began  leasing  approximately  1,100 square feet of administrative
space  in Costa Mesa, California at a monthly rental rate of $1,925 per month on
September 1, 2000. This facility serves as the Company's headquarters. The lease
is  scheduled  to  terminate  on  August  31,  2002.

The  Company's  subsidiary  Proteo  AG  has  rented office space to serve as its
headquarters  of approximately 170 sqft at a monthly rental rate of $320 ( 350).
This  lease  is expiring December 2003. Additional office space of approximately
1.500  sqft  is rented at a monthly rental rate of $660 ( 726) and utility costs
of  $250  (  276). The rental term is 10 years. Additionally, the subsidiary has
rented  facilities  to  carry  out  research  and  development of 2.800sqft at a
monthly  rental rate of $600 ( 660) and utility costs of $490 ( 536). The rental
term  is  10  years.


ITEM  3  -  LEGAL  PROCEEDINGS

The  Company  may  from  time  to  time be involved in various claims, lawsuits,
disputes with third parties, actions involving allegations of discrimination, or
breach  of  contract  actions  incidental to the operation of its business.  The
Company is not currently involved in any such litigation which it believes could
have  a  materially  adverse  effect  on  its  financial condition or results of
operations.


ITEM  4  -  SUBMISSION  OF  MATTERS  TO  A  VOTE  OF  SECURITY  HOLDERS

On  January  9,  the  majority  of  the Company's shareholder voted to amend the
Company's  Articles  of  Incorporation  and  to  change its name to Proteo, Inc.



<PAGE>
                                     PART II

ITEM  5  -  MARKET  FOR  COMMON  EQUITY  AND  RELATED  STOCKHOLDER  MATTERS

The  following  table  sets  forth the high and low bid prices for shares of the
Company  Common  Stock  for the periods noted, as reported by the National Daily
Quotation  Service,  the NASDAQ Bulletin Board, and the Pink Sheets.  Quotations
reflect inter-dealer prices, without retail mark-up, mark-down or commission and
may  not  represent  actual  transactions.  The  Company's  Common  Stock  was
originally listed on the NASDAQ Over-the-Counter Bulletin Board on April 2, 1998
under  the  trading  symbol  AFLK.  On  May  21,  1999, the Company's symbol was
changed to PAHI.  On October 12, 2001, the Company's symbol was changed to TVGE.
In  conjunction  with  the  Company's name change to Proteo, Inc., the Company's
symbol  was  changed  to  PTEO  on  January  28,  2002.

                         BID PRICES
     YEAR     PERIOD                      HIGH         LOW
                                         -------     -------
     1999      Third Quarter              20.00        0.50
               Fourth Quarter              1.50        0.25

     2000      First Quarter               1.00        0.15
               Second Quarter              0.50        0.14
               Third Quarter               0.25        0.06
               Fourth Quarter              0.25        0.06

     2001      First Quarter               N/A         N/A
               Second Quarter              N/A         N/A
               Third Quarter               N/A         N/A
               Fourth Quarter             34.50        3.00

     2002      First Quarter*               .51         .03
__________________
*Reflects reverse 1 for 150 reverse split effective January 28, 2002.

N/A - Not available.

NUMBER OF SHAREHOLDERS

The number of beneficial holders of record of the Common Stock of the company as
of  the close of business on February 28, 2002 was 1,737.  Many of the shares of
the  Company's  Common  Stock  are  held  in  "street name" and consequently may
reflect  numerous  additional  beneficial  owners.

DIVIDEND POLICY

To  date,  the  Company  has declared no cash dividends on its Common Stock, and
does  not expect to pay cash dividends in the near term.  The Company intends to
retain  future earnings, if any, to provide funds for operation of its business.

RECENT SALES OF UNREGISTERED SECURITIES

On  April  25,  2002,  pursuant  to an Agreement and Plan of Share Exchange, the
Company  issued  an  aggregate  of  20,286,512 shares of its common stock to the
shareholders  of  Proteo Marketing, Inc.  The shares were issued without general
solicitation  in  a  private  transaction  to foreign residents and "accredited"
domestic  residents  in  an  offering  exempt  from  registration  pursuant  to
Regulation  S  and  D  of  the  Securities  Act  of  1933.

ITEM  6.  PLAN  OF  OPERATIONS

CAUTIONARY  STATEMENTS:

This  Annual  Report  on Form 10-KSB contains certain forward-looking statements
within  the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of  the  Securities  Exchange  Act  of  1934.  The  Company  intends  that  such
forward-looking  statements  be  subject  to  the  safe  harbors created by such
statutes.  The  forward-looking  statements included herein are based on current
expectations  that involve a number of risks and uncertainties.  Accordingly, to
the extent that this Annual Report contains forward-looking statements regarding
the  financial  condition,  operating  results,  business prospects or any other
aspect  of  the  Company,  please  be  advised that the Company actual financial
condition, operating results and business performance may differ materially from
that  projected  or estimated by the Company in forward-looking statements.  The
differences  may be caused by a variety of factors, including but not limited to
adverse  economic  conditions, intense competition, including intensification of
price  competition  and  entry of new competitors and products, adverse federal,
state  and local government regulation, inadequate capital, unexpected costs and
operating  deficits,  increases in general and administrative costs, lower sales
and revenues than forecast, loss of customers, customer returns of products sold
to  them  by  the  Company,  termination  of  contracts,  loss  of  supplies,
technological  obsolescence  of  the Company's products, technical problems with
the  Company's  products, price increases for supplies and components, inability
to  raise prices, failure to obtain new customers, litigation and administrative
proceedings  involving  the  Company, the possible acquisition of new businesses
that result in operating losses or that do not perform as anticipated, resulting
in  unanticipated  losses,  the  possible  fluctuation  and  volatility  of  the
Company's  operating  results, financial condition and stock price, inability of
the  Company  to  continue as a going concern, losses incurred in litigating and
settling  cases,  adverse  publicity  and  news coverage, inability to carry out
marketing  and  sales  plans,  loss  or retirement of key executives, changes in
interest  rates,  inflationary  factors  and  other  specific  risks that may be
alluded  to in this Annual Report or in other reports issued by the Company.  In
addition,  the business and operations of the Company are subject to substantial
risks  that increase the uncertainty inherent in the forward-looking statements.
The  inclusion of forward looking statements in this Annual Report should not be
regarded  as  a  representation  by  the  Company  or  any other person that the
objectives  or  plans  of  the  Company  will  be  achieved.

The  Company's prior full fiscal year ending December 31, 2001 is not indicative
of  the  Company's  current  business  plan  and operations.  During the periods
ending  December  31,  2001  and December 31, 2000, the Company had little or no
revenues  and  was  in  its  development  stages.  After  the Share Exchange, as
previously  discussed,  the  Company's  current  business  plan was implemented.
Therefore,  this  plan of operation will focus on the Company's current business
plan and operations.  For information concerning the Company's prior full fiscal
years,  the Company refers the reader to the financial statements provided under
Part  F/S,  contained  herein.

The Company does not currently generate any revenue from its operations and does
not  expect to report any revenue until the successful development and marketing
of  its  planned pharmaceutical and other biotech products.  Additionally, after
the  launch of the Company's service, there can be no assurance that the Company
will  generate positive cash flow and there can be no assurances as to the level
of  revenues,  if  any,  the  Company  may  actually  achieve  from  its planned
operations.

Implementation Plan

The  Company intends to specialize in the research, development and marketing of
drugs  for inflammatory diseases with Elafin as its first project. The Company's
management  deems  Elafin  to  be  one of the most prospective substances in the
treatment  of  serious  tissue and muscle damage. Independently conducted animal
experiments  have  indicated  that  Elafin may have benefits in the treatment of
tissue  and muscle damage caused by insufficient oxygen supply and therefore may
be  useful in the treatment of heart attacks, serious injuries and in the course
of  organ  transplants.  Other  application  have  yet  to  be  determined.

The  Company  intends  to implement Elafin as a drug in the treatment of serious
tissue  and  muscle damage, e.g. due to traffic accidents and intends to achieve
governmental  approval  in  Europe first.  Currently, management assumes that it
will take at least five years to achieve first governmental approval for the use
of  Elafin  as  a drug in the treatment of serious tissue and muscle damage.  In
order  to  conduct  pre-clinical  and  clinical  trials,  the Company must first
complete  the  research  and  development  of an efficient production process in
accordance  with  GMP  (Good  Manufacturing  Practices)  standards.

The  Company's  success  will  depend  on  its  ability  to  implement efficient
production  process  in  accordance with GMP standards, to examine toxicology in
animal experiments, and to prove that Elafin is well tolerated by humans and its
efficiency  in  the  indicated  treatment.  There  can  be no assurance that the
Company  will  be  able  to develop feasible production procedures in accordance
with  GMP  standards,  or that Elafin will receive any governmental approval for
the  use  as  drug  in  any  of  the  intended  applications.

In  collaboration  with  a  non-affiliated  third party company, the Company has
identified  the yeast to be utilized in the production of Elafin and has ordered
the third party to develop efficient clones of such yeasts.  Simultaneously, the
Company  is  attempting  to  optimize  the  yeast expression systems to increase
efficient  production  of  such  yeasts.  Also, the Company is in the process of
equipping  its  recently  rented  facilities  and  to  scale up its fermentation
facilities  to  be able to produce sufficient amounts of Elafin for its research
and  development. The Company's management intends to have animal experiments on
the  toxicology  as  needed  to  enter governmental approval procedures in 2003.

LIQUIDITY  AND  CAPITAL  RESOURCES

Since  Inception,  the Company's wholly owned subsidiary, Proteo Marketing, Inc.
has raised a total of $1,500,000 from the sale of 500,000 shares of common stock
to  a German broker / dealer.  In addition, the Company sold 6,000,000 shares at
$0.40  per  share  to  the  same entity in exchange for a promissory note in the
amount  of  $2,400,000 bearing no interest.  As of March 31, 2002, the Company's
subsidiary  has  received  approximately  $212,000  from  the  note.

Additionally, the Company's wholly owned German subsidiary Proteo Biotech AG has
received  a  grant  from  the  German  state Schleswig-Holstein in the amount of
approximately  $700,000  (  770,000).  Such  grant shall cover 49.99% of related
costs  and  expenses of research and development of the Company's Elafin project
during  the  period  from 2001 to 2004 and will be offset against such costs and
expenses. The grant will depend on the Company's ability to cover 50.01% of such
costs  and  expenses,  and  from  the achievement of milestones. As of March 31,
2002,  the  Company  has  received $170,000 of the grant which have been set off
against  related  expenses.

The  Company's  cash  was  approximately  $530,000  as  of  March  31, 2002. The
Company's management assumes that the Company will not have significant revenues
within the next years, and therefore the success and the business of the Company
will  depend  mainly on its ability to utilize other means of funding as sale of
stock,  public  funding  or  loans.  However, there can be no assurance that the
Company  will  be  able  to  raise  sufficient  funds  to  support  its  product
development  and  overall  business.

CAPITAL  EXPENDITURES

TheEXPENDITURES  Company  intends  to equip its rented facilities to be eligible
for  the  Company's  research  and  development.  The  costs  are  estimated  at
approximately  $350,000.

ITEM  7  -  FINANCIAL  STATEMENTS

The  consolidated  financial statements and corresponding notes to the financial
statements  called  for by this item appear under the caption Index to Financial
Statements  (Page  F-1  hereof).

ITEM  8  -  CHANGES  IN  AND  DISAGREEMENTS  WITH  ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL  DISCLOSURE

Effective  February 11, 2002, the Board of Directors of the Company approved the
engagement  of Squar, Milner, Reehl & Williamson, LLP Public Accountants ("Squar
Milner") as its independent auditors for the fiscal year ended December 31, 2001
to replace Stonefield Josephson, Inc. (Stonefield Josephson").   The Company did
not  consult  with  Squar  Milner  on  any  matters  prior  to  their retention.

The report of Stonefield Josephson on the Company's financial statements for the
fiscal  year  ended December 31, 2000, and the related statements of operations,
stockholder's equity and cash flows for the two years then ended did not contain
an adverse opinion or a disclaimer of opinion and were not qualified or modified
as  to  uncertainty,  audit  scope,  or  accounting  principles.

During the two most recent fiscal years and any subsequent interim period, there
were  no  disagreements  with  Stonefield Josephson on any matters of accounting
principles  or  practices, financial statement disclosure, or auditing scope and
procedures  which,  if  not resolved to the satisfaction of Stonefield Josephson
would  have caused Stonefield Josephson to make reference to the matter in their
report.

Effective March 29, 2002, the Board of Directors of the Company dismissed Squar,
Milner,  Reehl & Williamson ("Squar Milner") as its independent auditors for the
fiscal year ended December 31, 2001 and approved the re-engagement of Stonefield
Josephson,  Inc.  ("Stonefield  Josephson")  as  Squar  Milner's  replacement.
Stonefield  Josephson  had  previously  been the Company's independent auditors.
The  decision  to  change  auditors  was  approved  by  the  Company's  Board of
Directors.

Squar  Milner  had  not  audited  or  reviewed  any  of  the Company's financial
statements  or  issued any other report to the Company.  Since the date of their
engagement  on  February  11,  2002, there have been no disagreements with Squar
Milner on any matters of accounting principles or practices, financial statement
disclosure,  or  auditing  scope  or  procedure  which,  if  not resolved to the
satisfaction of Squar Milner would have caused Squar Milner to make reference to
the  matter  in  their  report.




<PAGE>
                                    PART III

ITEMS  9  -  DIRECTORS,  EXECUTIVE  OFFCIERS,  PROMOTERS  AND  CONTROL  PERSON;
COMPLIANCE  WITH  SECTION  16  (A)  OF  THE  EXCHANGE  ACT

     The  following  table  sets  forth  the  names  and ages of the current and
incoming  directors and executive officers of the Company, the principal offices
and  positions  with  the  Company  held by each person and the date such person
became  a  director or executive officer of the Company.  The executive officers
of  the  Company  are elected annually by the Board of Directors.  The directors
serve one year terms until their successors are elected.  The executive officers
serve  terms  of  one  year  or until their death, resignation or removal by the
Board  of  Directors.  Unless described below, there are no family relationships
among  any  of  the  directors  and  officers.

     Name                         Age     Positions

     Joerg  Alte                   41     President,  Chief  Executive Officer,
                                          Chief Financial Officer, and Director

     Professor Oliver Wiedow, MD.  44     Director

     Birge  Bargmann               41     Director

     Holger  Pusch                 45     Director

     Ulrich  Glaeser               44     Secretary  and  Director

     Hartmut  Weigelt,  Ph.D.      56     Director

Biographical  Information:

     Joerg  Alte,  currently  serves  as the President, Chief Executive Officer,
Chief  Financial  Officer  and  Director  of  the Company.  Mr. Alte is a German
lawyer  by  training  and  practice.  After  studying law and passing his second
state  examination,  he  worked for more than three years at a German law office
predominantly  engaged  in  economic  and  corporate  laws  with both public and
private  company  clients  engaged  in international business. Subsequently, Mr.
Alte  worked  as a legal advisor with a German diagnostic company, where he also
practiced  German  and  U.S. Securities laws.  From November 1998 to April 2000,
Mr.  Alte  served as President and CEO for Sangui BioTech International, Inc., a
publicly  traded  company.

     Prof.  Oliver  Wiedow, M.D., currently serves as a Director of the Company.
Since  1985  Professor  Wiedow  has  served  as  physician  and scientist at the
University  of  Kiel,  Germany.  Currently,  Prof.  Wiedow  is  a  Professor  of
dermatology,  venerology  and  allergology  at  the  university's dermatological
clinic.  Mr.  Wiedow  discovered  Elafin  in  human  skin and has researched its
biological  effects.  He  has  knowledge in biochemistry which is needed for the
production  of  Elafin.

     Birge Bargmann, currently serves as a Director of the Company.  Since 1989,
Ms.  Bargmann  has worked as a medical technique assistant engaged in the Elafin
project  at  the  dermatological  clinic  of  the  University  of  Kiel.  She
co-developed  and  carried  out  procedures  to  detect  and to clean up Elafin.

     Holger  Pusch,  currently serves as a Director of the Company. Mr. Pusch is
presently  employed by Agfa-Gaevert. For the last 15 years, Mr. Pusch has worked
in  different  marketing  and  sales functions for major German companies, among
others  as  Director  of  Marketing  and  Division  Leader.

     Ulrich  Glaeser,  currently  serves  as  Secretary and as a Director of the
Company.  Before  joining  Proteo AG as Chief Executive Officer in May 2001, Mr.
Glaeser  was  sales  and  marketing  manager at Draeger ProTech GmbH in Luebeck,
Germany.  In  addition  to  his  degrees  in economics and engineering, he has a
Master  of  Business  Marketing (MBM) degree from the Free University of Berlin.

     Hartmut  Weigelt,  Ph.D.,  currently  serves  as a Director of the Company.
Since  1996,  Mr. Weigelt has served as the managing director of Eco Impact GmbH
which  he  co-founded.  Between  1995  and 1996, Mr. Weigelt was the Director of
Environmental  Agency  for the city of Dortmund, Germany.  From 1992 to 1994 Mr.
Weigelt  served  as the managing directgor of Environmental Resources Management
GmbH.  From  1989  to  1992 Mr. Weigelt worked as the Director for Environmental
Risk-Analysis and Business Coordination for Gerling AG (a large German insurance
company).  From  1987  to  1989  Mr.  Weigelt  worked  as  the  Director  for
Drug-Development-Coordination  of Schering AG (a German pharmaceutical company).
Between  1972  to  1985,  Mr.  Weigelt  worked  for  Max-Planck-Institute  for
Systems-Physiology.  Mr.  Weigelt  was  also  a  co-founder  of the first German
private  university, Witten/Herdecke.  Mr. Weigelt studied chemistry and biology
and  graduated  with  a  M.Sc.,  Ph.D.,  and  D.Sc.  in  biology.

COMPLIANCE  WITH  SECTION  16(A)  OF  THE  SECURITIES  EXCHANGE  ACT  OF  1934.

     Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
directors  and executive officers and persons who own more than ten percent of a
registered class of the Company's equity securities to file with the SEC initial
reports  of  ownership  and  reports of changes in ownership of Common Stock and
other  equity  securities  of the Company.  Officers, directors and greater than
ten  percent shareholders are required by SEC regulations to furnish the Company
with  copies  of  all Section 16(a) forms they file. To the Company's knowledge,
based  solely  on  the review of copies of such reports furnished to the Company
and written representations that no other reports were required, the Company has
been  informed  that  all  Section  16(a)  filing requirements applicable to the
Company's  officers,  directors  and  greater than ten percent shareholders were
complied  with.

ITEM  10  -  EXECUTIVE  COMPENSATION

     The  following  Summary  Compensation  Table  shows  certain  compensation
information  for  services rendered in all capacities for the fiscal years ended
December  31,  1998  and  1999.  Other  than  as  set forth herein, no executive
officer's  salary  and  bonus  exceeded $100,000 in any of the applicable years.
The  following  information  includes  the  dollar value of base salaries, bonus
awards,  the  number of stock options granted and certain other compensation, if
any,  whether  paid  or  deferred.

Summary  Compensation  Table
----------------------------

     The  Summary  Compensation Table shows certain compensation information for
services rendered in all capacities for the fiscal years ended December 31, 1998
and  1999.  Other  than  as  set forth herein, no executive officer's salary and
bonus  exceeded  $100,000  in  any  of  the  applicable  years.  The  following
information includes the dollar value of base salaries, bonus awards, the number
of stock options granted and certain other compensation, if any, whether paid or
deferred.

<TABLE>
<CAPTION>
                                                             SUMMARY COMPENSATION TABLE

                                          ANNUAL  COMPENSATION                          LONG  TERM  COMPENSATION
                                         ----------------------                         AWARDS           PAYOUTS
                                                                                    -------------------------------
                                                                OTHER        RESTRICTED  SECURITIES                 ALL
NAME AND                                                        ANNUAL         STOCK     UNDERLYING    LTIP        OTHER
PRINCIPAL                          SALARY        BONUS       COMPENSATION      AWARDS     OPTIONS     PAYOUTS   COMPESATION
POSITION               YEAR         ($)           ($)            ($)            ($)       SARS (#)      ($)         ($)
---------------------------------------------------------------------------------------------------------------------------
<S>                   <C>       <C>             <C>          <C>               <C>       <C>          <C>       <C>
Earl T. Shannon       2000      $   60,000        -0-             -0-           -0-        500,000      -0-         -0-
(President,
Secretary,
Treasurer, Director)  1999      $   60,000        -0-             -0-           -0-        500,000      -0-         -0-

</TABLE>

(1)     Mr. Shannon is no longer affiliated with the Company.


<TABLE>
<CAPTION>


                                   OPTION/SAR GRANTS IN LAST FISCAL YEAR
                                            (INDIVIDUAL GRANTS)


                  NUMBER OF SECURITIES      PERCENT OF TOTAL
                       UNDERLYING         OPTIONS/SAR'S GRANTED
                 OPTIONS/SAR'S GRANTED   TO EMPLOYEES IN FISCAL    EXERCISE OF BASE PRICE
NAME                      (#)                     YEAR                     ($/SH)           EXPIRATION DATE
                 ----------------------  -----------------------  ------------------------  ---------------
<S>                         <C>                     <C>                      <C>                       <C>
Earl T. Shannon         500,000                    33.3%                    $0.15          10/27/05

</TABLE>

(1)  These options have all been terminated.


<TABLE>
<CAPTION>



                                   AGGREGATED OPTION/SAR EXERCISES IN LAST FISCAL YEAR
                                               AND FY-END OPTION/SAR VALUES


                                                                   NUMBER OF UNEXERCISED      VALUE OF UNEXERCISED IN
                                                                   SECURITIES UNDERLYING       THE-MONEY OPTION/SARS
                   SHARES ACQUIRED ON             VALUE            OPTIONS/SARS AT FY-END (#)        AT FY-END ($)
NAME                  EXERCISE (#)             REALIZED ($)        EXERCISABLE/UNEXERCISABLE   EXERCISABLE/UNEXERCISABLE
                 ----------------------  ------------------------  --------------------------  --------------------------
<S>                        <C>                     <C>                       <C>                         <C>

Earl T. Shannon            -0-                    -0-                         -0-                       -0-

</TABLE>

Compensation of Directors

     The  Directors  have  not  received  any  compensation  for serving in such
capacity,  and  the  Company  does  not  currently  contemplate compensating its
Directors  in  the  future  for  serving  in  such  capacity.


<PAGE>
ITEM 11 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The  following  table sets forth, as of April 30, 2002, certain information with
respect  to  the  Company's equity securities owned of record or beneficially by
(i)  each  Officer  and  Director  of  the  Company;  (ii)  each person who owns
beneficially  more  than  5%  of  each class of the Company's outstanding equity
securities;  and  (iii)  all  Directors  and Executive Officers as a group.  The
address  for  all of the following entities and individuals is c/o Proteo, Inc.,
2775  Mesa  Verde  Drive  East,  #F101,  Costa  Mesa,  CA  92626.

<TABLE>
<CAPTION>

                              Name and Address of     Amount and Nature of       Percent
Title of Class                Beneficial Owner        Beneficial Ownership (1)   of Class
----------------------------  ----------------------  ------------------------   --------
<S>                           <C>                     <C>                        <C>
Common                        Oliver Wiedow
Stock                                                      10,680,000            52.31%

Common                        Birge Bargmann
Stock                                                       2,000,000             9.80%

Common                        Holger Pusch
Stock                                                          20,000             0.10%

Common                        Ulrich Glaeser
Stock                                                         100,000             0.49%

Common                        Hartmut Weigelt
Stock                                                         150,000             0.73%

Common                        Joerg Alte
Stock                                                         140,000             0.69%

Common                        All officers and directors
Stock                          as a group (6 persons)      13,090,000            64.12%

</TABLE>

(1)     Based on 20,415,444 shares outstanding.

ITEM 12 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

     On  April 25, 2001, the Company entered into an Agreement and Plan of Share
Exchange  with  Proteo Marketing, Inc. whereby all of the shareholders of Proteo
Marketing,  Inc.  would exchange their shares Proteo Marketing's common stock in
exchange  for  20,286,512  on  a  one-for-one  basis.  As  a  result,  of  the
transaction,  effective  April 26, 2002, Proteo Marketing, became a wholly owned
subsidiary  of  the  Company.

     On  December  28,  2001,  the  Company  entered  into the Shell Acquisition
Agreement  which  resulted in a restructuring of the Company's management, Board
of  Directors,  and  ownership.  Many  of  the  directors and officers of Proteo
Marketing,  Inc.  became  directors,  officers  of  the  Company.

     The  Company  has  agreed  to  pay Prof. Wiedow, a director of the Company,
three  percent  (3%)  of  the  gross  revenues of Company from products based on
patents  where  he  was  the  principal  inventor.  Furthermore, the Company has
agreed  to  pay  licensing  fees  in  the  amount of 110,000 Euro (approximately
$100,000)  per year and a refund for all expenses needed to maintain the patents
(e.g.,  patent  fees,  lawyers  fees,  etc).

<PAGE>

     AstraZeneca,  Inc.  (formerly  Zeneca,  Inc., formerly ICI Pharmaceuticals,
Inc.)  has  held  the  patents for Elafin (Proteo's primary product) for several
years and has significantly contributed to the current knowledge. Therefore, the
Company  has  agreed  to pay AstraZeneca Inc. 2% of the gross revenues of Proteo
and  the Subsidiary from products based on patents in which Prof. Wiedow was the
principal  inventor.

     The  officers  and  directors  of  the  Company  may  be  engaged  in other
businesses,  either  individually  or  through  partnerships and corporations in
which  they  have  ownership  interests,  hold  offices  or  serve  on Boards of
Directors.

     The Company will attempt to resolve any such conflicts of interest in favor
of the Company. The officers and directors of the Company are accountable to the
Company  and  the  Company's  shareholders  as  fiduciaries.

ITEM  13  -  EXHIBITS  AND  REPORTS  ON  FORM  8-K

(A)  EXHIBITS

EXHIBIT
NO.     DESCRIPTION

2.1+    Agreement and Plan of Share Exchange

3.1*    Articles of Incorporation, dated December 18, 1992

3.2*    Amendment to Articles of Incorporation, dated October 31, 1996

3.3*    Amendment to Articles of Incorporation, dated February 12, 1998

3.4*    Amendment to Articles of Incorporation, dated May 18, 1999

3.5     Amendment to Articles of Incorporation, dated July 18, 2001

3.6     Amendment to Articles of Incorporation, dated January 11, 2002

3.7+    Articles of Share Exchange, dated April 25, 2002

3.8*    By-Laws, dated December 18, 1992

21      Subsidiaries of the Registrant

________________________
+ Incorporated by reference from the Company's Current Report on Form 8-K filed
  on May 6, 2002

* Incorporated by reference from the Company's Registration Statement on Form
10-SB filed with the SEC on March 2, 1999.

(B)  REPORTS  ON  FORM  8-K

On  January 15, 2002, the Company filed a Current Report on form 8-K reporting a
change  in  control.

On  February  15,  2002,  as  amended  on February 27, 2002, the Company filed a
Current  Report  on  form  8-K  reporting  a  change  in its auditors of record.

On  April 5, 2002, Company filed a Current Report on form 8-K reporting a change
in  its  auditors  of  record.

On  April 5, 2002, Company filed a Current Report on form 8-K reporting the
completion of its Share Exchange with Proteo Marketing, Inc.

<PAGE>
                                   SIGNATURES

Pursuant  to  the requirements of Section 13 or 15(d) of the Securities Exchange
Act  of  1934,  the  registrant  has duly caused this report to be signed on its
behalf  by  the  undersigned,  thereunto  duly  authorized.


Dated:  May 9,  2002

                                     PROTEO, INC
                                     (Registrant)

                                     By: /s/  Joerg  Alte
                                     --------------------------
                                     Joerg Alte,
                                     Chief Executive Officer,
                                     Chief Financial Officer and Director

Pursuant to requirements of the Securities Exchange Act of 1934, this report has
been  signed  below  by the following persons on behalf of the registrant and in
the  capacities  and  on  the  dates  indicated:

     Signature                         Capacity            Date
     ---------------------------------------------------------------

     Professor Oliver Wiedow, MD.      Director          May 9, 2002

     Birge  Bargmann                   Director          May 9, 2002

     Holger  Pusch                     Director          May 9, 2002

     Ulrich  Glaeser                   Director          May 9, 2002

     Hartmut  Weigelt,  Ph.D.          Director          May 9, 2002


<PAGE>
                         INDEPENDENT AUDITORS' REPORT


Board  Of  Directors
Proteo,  Inc.
Sherman  Oaks,  California

We  have  audited  the  accompanying  balance  sheet  of  Proteo, Inc. (formerly
Trivantage  Group,  Inc.) as of December 31, 2001, and the related statements of
operations, stockholder's deficiency and cash flows for each of the two years in
the  period  ended  December  31,  2001.  These  financial  statements  are  the
responsibility  of  the Company's management.   Our responsibility is to express
an  opinion  on  these  financial  statements  based  on  our  audits.

We conducted our audits in accordance with auditing standards generally accepted
in  the  United  States  of  America.  Those  standards require that we plan and
perform  the  audit  to  obtain reasonable assurance about whether the financial
statements are free of material misstatement.  An audit includes examining, on a
test  basis,  evidence  supporting  the amounts and disclosures in the financial
statements.  An audit also includes assessing the accounting principles used and
significant  estimates  made  by  management,  as well as evaluating the overall
financial  statement  presentation.  We  believe  that  our  audits  provide  a
reasonable  basis  for  our  opinion.

In  our  opinion,  the financial statements referred to above present fairly, in
all material respects, the financial position of Proteo, Inc. as of December 31,
2001,  and  the results of its operations and its cash flows for each of the two
years  in  the  period  ended  December  31, 2001, in conformity with accounting
principles  generally  accepted  in  the  United  States  of  America.

The  accompanying  financial  statements  have  been  prepared assuming that the
Company  will  continue as a going concern.  As discussed in Note 1, the Company
has  no  operations  raises substantial doubt about its ability to continue as a
going  concern.  Management's  plans concerning these matters are also discussed
in  Note  1.  The financial statements do not include any adjustments that might
result  from  the  outcome  of  this  uncertainty.





CERTIFIED  PUBLIC  ACCOUNTANTS


Santa  Monica,  California
April 12,  2002

<PAGE>

<TABLE>
<CAPTION>

                                  PROTEO, INC.

                        BALANCE SHEET - DECEMBER 31, 2001

                                     ASSETS



<S>                                                       <C>

TOTAL ASSETS                                              $      -
                                                          ========


LIABILITIES AND STOCKHOLDER'S EQUITY (DEFICIENCY)

TOTAL LIABILITIES                                         $      -

STOCKHOLDERS' EQUITY (DEFICIENCY):
  Preferred stock; $0.001 par value, 10,000,000 shares
    authorized, no shares issued and outstanding          $      -
   Common Stock; $0.001 par value, 300,000,000 shares
    authorized, 1,308,594 shares issued and outstanding      1,308
   Additional paid in capital                               (1,308)
   Accumulated deficit                                    $      -
                                                          --------
     Total stockholder's equity (deficiency)              $      -
                                                          --------

                                                          $
                                                          ========



</TABLE>

See accompanying independent auditors' report and notes to financial statements.


<PAGE>

<TABLE>
<CAPTION>


                                          PROTEO, INC.

                                   STATEMENTS  OF  OPERATIONS





                                                                      Year ended          Year ended
                                                                      December 31, 2001   December 31, 2000
                                                                      ------------------  -------------------
<S>                                                                   <C>                 <C>

REVENUE                                                               $               -    $               -

COST OF REVENUE                                                                       -                    -
                                                                      ------------------  -------------------

GROSS PROFIT                                                                          -                    -

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES                                          -                    -
                                                                      ------------------  -------------------

INCOME (LOSS) FROM CONTINUED OPERATIONS                                               -                    -
                                                                      ------------------  -------------------


DISCONTINUED OPERATIONS:
  Income (loss) on discontinued operations, net of $0 tax effect                   8,321             (83,043)
  Gain on disposal of discontinued operations, net of $0 tax effect              150,625                   -
                                                                      ------------------  -------------------

NET INCOME (LOSS)                                                     $          158,946  $          (83,043)
                                                                      ==================  ===================

INCOME (LOSS) PER SHARE - basic and diluted
  Continued operations                                                $             0.01  $            (0.06)
  Discontinued operations                                                           0.12
                                                                      ------------------  -------------------
  Net income (loss)                                                   $             0.13  $            (0.06)
                                                                      ==================  ===================

WEIGHTED AVERAGE SHARES OUTSTANDING -
  basic and diluted                                                            1,308,594           1,308,594
                                                                      ==================  ===================

</TABLE>

See accompanying independent auditors' report and notes to financial statements.


<PAGE>

<TABLE>
<CAPTION>


                                       PROTEO, INC.

                          STATEMENT OF STOCKHOLDER'S DEFICIENCY




                                                        Additional                 Total
                                     Common  stock        paid-in  Accumulated  stockholders'
                                   Shares       Amount    capital    deficit     deficiency
                                  ----------  --------- ---------- ---------   ----------
<S>                               <C>         <C>        <C>       <C>         <C>
Balance at January 1, 2000        1,177,735   $  1,177   $(1,177)  $ (75,903)  $ (75,903)

Net loss                                  -          -         -     (83,043)    (83,043)
                                  ----------  --------- ---------- ---------   ----------

Balance at December 31, 2000      1,177,735      1,177    (1,177)   (158,946)   (158,946)

Shares issued for acquisition of
 PageActive Holdings, Inc.          130,859        131      (131)          -           -

Net loss                                  -          -         -     158,946     158,946
                                  ----------  --------- ---------- ---------   ----------

Balance at December 31, 2001      1,308,594   $  1,308   $(1,308)  $       -    $       -
                                  ==========  ========= ========== =========   ==========


</TABLE>


See accompanying independent auditors' report and notes to financial statements.

<PAGE>



<TABLE>
<CAPTION>



                                           PROTEO, INC.

                                     STATEMENTS OF CASH FLOWS




                                                              Year ended          Year ended
                                                          December 31, 2001    December 31, 2000
                                                          ------------------  -------------------
<S>                                                       <C>                 <C>
NET INCOME / (LOSS) FOR DISCONTINUED OPERATIONS           $         158,946   $          (83,043)

CASH FLOWS PROVIDED BY (USED FOR) FINANCING ACTIVITIES -
  due to parent, net                                               (158,946)  $           83,043
                                                          ------------------  -------------------

NET DECREASE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, beginning of year

CASH AND CASH EQUIVALENTS, end of year                    $                -   $               -
                                                          ==================  ===================

SUPPLEMENTAL  DISCLOSURE  OF  CASH  FLOW  INFORMATION:
  During  the  years  ended  December  31,  2001  and  2000,
  the  Company  paid  no  income  taxes  and  no  interest.

SUPPLEMENTAL  DISCLOSURE  FOR  NON-CASH  INVESTING  AND  FINANCING  ACTIVITIES:
During  the year ended December 31, 2001, the parent company repurchased all the
assets  and  liabilities  of  the  Company  in  exchange for cancellation of the
amounts  due  to  parent.

</TABLE>

See accompanying independent auditors' report and notes to financial statements.



<PAGE>


                                  PROTEO, INC.
                          NOTES TO FINANCIAL STATEMENTS
                     YEARS ENDED DECEMBER 31, 2001 AND 2000


(1)     SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES:

ORGANIZATION:

Proteo,  Inc. (the "Company") was organized on December 18, 1992, under the laws
of  the  State  of Nevada as The Flintlock Company. On May 18, 1999, the name of
the  Company  was  changed  from  the  American  Flintlock Company to PageActive
Holdings,  Inc.  On  July  11,  2001,  the  name  of  the Company was changed to
TriVantage  Group,  Inc.  and  on  January 11, 2002, the name of the Company was
changed  to  Proteo,  Inc.

Sitestar  Applied  Technologies,  Inc.  ("SAT")  was  incorporated  in Nevada on
October 12, 2000. SAT is a wholly-owned subsidiary of Sitestar.net, Inc. ("SDN")
which  is  a wholly-owned subsidiary of Sitestar Corporation. Upon the formation
of  SAT,  SDN  contributed  all of the assets and liabilities of its development
division  to SAT in exchange for 100% of the issued and outstanding common stock
of  SAT.

MERGERS  AND  ACQUISITIONS:

On  July  11,  2001,  the  Company  completed  an  acquisition transaction  (the
"Acquisition") in accordance with a Plan of Reorganization and Acquisition dated
June  1,  2001,  with  SAT.  As  a  consequence of the Acquisition, SAT became a
wholly-owned  subsidiary  of  TriVantage Group, Inc. ("TriVantage") and Sitestar
Corporation,  the  parent  company  of  SDN  became  a  major shareholder owning
1,177,735  shares,  representing  approximately  90%  of  the  total  issued and
outstanding  common  stock  of TriVantage. The acquisition of SAT by the Company
has  been  accounted  for as a reverse merger.  Prior to the merger, the Company
had  no  business  activity  and therefore pro forma operating results as if the
acquisition  had taken place at the beginning of the periods presented, have not
been  presented.  For  accounting purposes, SAT has been treated as the acquirer
and  accordingly,  SAT is presented as the continuing entity, and the historical
financial  statements  are  those  of  SAT.

On  December  28,  2001,  SDN  repurchased  ("Repurchase") all of the assets and
liabilities  of SAT in exchange for the cancellation of the intercompany payable
due  to  SDN,  as of the date of the Repurchase. Also, on December 28, 2001, the
Company  entered  into  a  Shell  Acquisition  Agreement  (the  "Acquisition
Agreement")  with  Proteo,  Inc.,  a  Nevada  corporation  ("Old Proteo"), which
results  in a restructuring of the Company's management, Board of Directors, and
ownership.  In  accordance with the Acquisition Agreement, Proteo, Inc. acquired
1,177,735  shares  of the Company's common stock, representing approximately 90%
of  the  issued  and  outstanding  common  stock  of  the  Company.




See  accompanying  independent  auditors'  report.

<PAGE>
                                  PROTEO, INC.
                    NOTES TO FINANCIAL STATEMENTS (CONTINUED)
                     YEARS ENDED DECEMBER 31, 2001 AND 2000



(1)     SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES,  CONTINUED:

MERGERS  AND  ACQUISITIONS,  CONTINUED:

Upon  completion  of  the  Acquisition  Agreement,  the  name of the Company was
changed  to  Proteo,  Inc.  Simultaneously  with  the  name  change, the Company
completed  a  one  for  one  hundred  fifty  reverse  stock  split of its equity
securities  (all  applicable  share  and  share  data  has been adjusted for the
reverse  stock  split).  Following completion of the reverse stock split and the
name  change,  the Company was to issue an aggregate of 20,286,512 shares to the
shareholders  of  Proteo  Marketing,  Inc., a wholly owned subsidiary of Proteo,
Inc.  in  consideration  for  their  Proteo  Marketing,  Inc. shares to effect a
reverse  acquisition between the Company and Proteo Marketing, Inc.  As of April
25,  2002,  the  reverse  acquisition with Proteo Marketing, Inc. was completed.

BASIS  OF  PRESENTATION:

The  accompanying  financial  statements  have  been  prepared assuming that the
Company  will  continue  as  a  going  concern.  As  shown  in  the accompanying
financial statements, the Company has no operations.  Management intends to seek
a  merger  with  a  company  that  has  sustainable  operations.

USE  OF  ESTIMATES:

The preparation of financial statements in conformity with accounting principles
generally  accepted  in the United States of America requires management to make
estimates  and  assumptions  that  affect  the  reported  amounts  of assets and
liabilities  and disclosures of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenue and expenses during
the  reporting  periods.  Actual  results  could  differ  from  these estimates.

EXPENSE  ALLOCATIONS:

The Company is located and shares office space with its parent, Sitestar.net and
as  a result the two companies shares many of the general and administrative and
overhead  expense associated with operating the two companies.  Principally, the
allocation  of general and administrative and overhead expenses are allocated to
the  Company  based  upon a percentage of its revenue compared to the revenue of
its  parent.

INCOME  TAXES:

The  Company  accounts  for  income  taxes  in  accordance  with  SFAS  No. 109,
"Accounting  for  Income  Taxes".  Deferred  taxes  are  provided on a liability
method  whereby  deferred  tax  assets  are  recognized for deductible temporary
differences,  and  deferred tax liabilities are recognized for taxable temporary
differences.  Temporary  differences  are  the  differences between the reported
amounts  of assets and liabilities and their tax bases.  Deferred tax assets are
reduced  by a valuation allowance when, in the opinion of management, it is more
likely  than  not  that  some  portion or all of the deferred tax assets will be
realized.  Deferred  tax  assets and liabilities are adjusted for the effects of
changes  in  tax  laws  and  rates  on  the  date  of  enactment.


See  accompanying  independent  auditors'  report.

<PAGE>
                                  PROTEO, INC.
                    NOTES TO FINANCIAL STATEMENTS (CONTINUED)
                     YEARS ENDED DECEMBER 31, 2001 AND 2000


(1)     SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES,  CONTINUED:

LOSS  PER  SHARE:

In  accordance  with  SFAS  No.  128,  "Earnings  Per Share", the basic loss per
common  share  is computed by dividing net loss available to common stockholders
by  the  weighted average number of common shares outstanding.  Diluted loss per
common  share is computed similar to basic loss per common share except that the
denominator  is increased to include the number of additional common shares that
would  have  been outstanding if the potential common shares had been issued and
if  the  additional common shares were dilutive.  The Company has no potentially
dilutive  securities.

COMPREHENSIVE  INCOME:

SFAS  No.  130,  "Reporting Comprehensive Income", establishes standards for the
reporting  and  display  of  comprehensive  income  and  its  components  in the
financial  statements.  As  of  December  31,  2001 and 2000, the Company has no
items that represent other comprehensive income and, therefore, has not included
a  schedule  of  comprehensive  income  in  the  financial  statements.

RECENTLY  ISSUED  ACCOUNTING  PRONOUNCEMENTS:

In  July  2001,  the FASB issued SFAS No. 141 "Business Combinations."  SFAS No.
141  supersedes Accounting Principles Board ("APB") No. 16 and requires that any
business  combinations  initiated  after  June  30,  2001  be accounted for as a
purchase;  therefore,  eliminating the pooling-of-interest method defined in APB
16.  The  statement  is  effective  for any business combination initiated after
June  30, 2001 and shall apply to all business combinations accounted for by the
purchase method for which the date of acquisition is July 1, 2001 or later.  The
Company  adopted  SFAS  No. 141 on July 1, 2001 and the adoption had no material
impact  on  the  Company's  financial  position  or  results  of  operations.

In  July  2001,  the FASB issued SFAS No. 142, "Goodwill and Other Intangibles."
SFAS  No. 142 addresses the initial recognition, measurement and amortization of
intangible assets acquired individually or with a group of other assets (but not
those  acquired  in  a  business  combination)  and  addresses  the amortization
provisions for excess cost over fair value of net assets acquired or intangibles
acquired in a business combination.  The statement is effective for fiscal years
beginning  after  December  15,  2001,  and  is  effective  July 1, 2001 for any
intangibles  acquired  in  a business combination initiated after June 30, 2001.
The  Company  is  evaluating  any  accounting  effect,  if any, arising from the
recently  issued SFAS No. 142, "Goodwill and Other Intangibles" on the Company's
financial  position  or  results  of  operations.




See  accompanying  independent  auditors'  report.

<PAGE>
                                  PROTEO, INC.
                    NOTES TO FINANCIAL STATEMENTS (CONTINUED)
                     YEARS ENDED DECEMBER 31, 2001 AND 2000

(1)     SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES,  CONTINUED:

RECENTLY  ISSUED  ACCOUNTING  PRONOUNCEMENTS,  CONTINUED:

In  October  2001,  the FASB recently issued SFAS No. 143, "Accounting for Asset
Retirement  Obligations," which requires companies to record the fair value of a
liability  for  asset  retirement  obligations  in  the period in which they are
incurred.  The  statement  applies  to  a company's legal obligations associated
with  the  retirement  of  a  tangible  long-lived  asset  that results from the
acquisition,  construction, and development or through the normal operation of a
long-lived  asset.  When  a  liability  is initially recorded, the company would
capitalize  the  cost,  thereby  increasing  the  carrying amount of the related
asset.  The  capitalized  asset  retirement cost is depreciated over the life of
the respective asset while the liability is accreted to its present value.  Upon
settlement of the liability, the obligation is settled at its recorded amount or
the  company  incurs a gain or loss. The statement is effective for fiscal years
beginning after June 30, 2002.  The Company does not expect the adoption to have
a  material impact to the Company's financial position or results of operations.

In October 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or
Disposal  of  Long-Lived  Assets".  Statement  144  addresses the accounting and
reporting  for  the  impairment  or disposal of long-lived assets. The statement
provides a single accounting model for long-lived assets to be disposed of.  New
criteria  must  be  met  to  classify  the asset as an asset held-for-sale. This
statement  also focuses on reporting the effects of a disposal of a segment of a
business.  This statement is effective for fiscal years beginning after December
15, 2001.  The Company does not expect the adoption to have a material impact to
the  Company's  financial  position  or  results  of  operations.